Kalaris Therapeutics Inc
KLRS10.060USD
+0.930+10.19%
收盘 12/22, 16:00（美东）报价延迟15分钟
188.15M总市值
亏损市盈率 TTM
关于 Kalaris Therapeutics Inc 公司
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc简介
公司代码KLRS
公司名称Kalaris Therapeutics Inc
上市日期Jul 30, 2020
CEOOxtoby (Andrew)
员工数量6
证券类型Ordinary Share
年结日Jul 30
公司地址400 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编07922
电话16502492727
网址https://kalaristx.com/
公司代码KLRS
上市日期Jul 30, 2020
CEOOxtoby (Andrew)
Kalaris Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
收入明细
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
其他
27.70%
持股股东
持股股东
占比
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
其他
27.70%
股东类型
持股股东
占比
Venture Capital
61.21%
Individual Investor
6.43%
Corporation
6.16%
Hedge Fund
4.35%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
1.42%
其他
16.59%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
193
13.23M
70.72%
-1.05M
2025Q2
227
16.58M
88.66%
+10.64M
2025Q1
234
16.39M
87.75%
+10.95M
2024Q4
237
3.88M
53.28%
-1.58M
2024Q3
243
4.43M
85.21%
-1.20M
2024Q2
253
4.51M
86.91%
-1.04M
2024Q1
252
4.61M
89.02%
-783.99K
2023Q4
254
4.25M
88.46%
-716.47K
2023Q3
253
4.79M
104.12%
+25.72K
2023Q2
259
4.80M
104.70%
+638.53K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Samsara BioCapital, LLC
11.45M
61.21%
--
--
Jun 30, 2025
ElevateBio LLC
724.99K
3.88%
--
--
Jun 25, 2025
Ferrara (Napoleone)
504.00K
2.69%
--
--
Jun 25, 2025
F2 MG Ltd
427.31K
2.28%
-1.00
-0.00%
Jun 25, 2025
Tang Capital Management, LLC
360.86K
1.93%
+51.64K
+16.70%
Jun 30, 2025
Invus Public Equities Advisors, LLC
282.59K
1.51%
--
--
Jun 30, 2025
Patel (Samirbhai Chandrakant)
252.00K
1.35%
+252.00K
--
Mar 18, 2025
Rezai (Kourous)
203.67K
1.09%
+203.67K
--
Jun 25, 2025
The Vanguard Group, Inc.
129.84K
0.69%
+14.75K
+12.82%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
Avantis US Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Avantis US Small Cap Equity ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Schwab U.S. Broad Market ETF
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jan 10, 2025
Merger
23→1
公告日期
类型
比率
Jan 10, 2025
Merger
23→1
常见问题
Kalaris Therapeutics Inc的前五大股东是谁？
Kalaris Therapeutics Inc 的前五大股东如下：
Samsara BioCapital, LLC持有股份：11.45M，占总股份比例：61.21%。
ElevateBio LLC持有股份：724.99K，占总股份比例：3.88%。
Ferrara (Napoleone)持有股份：504.00K，占总股份比例：2.69%。
F2 MG Ltd持有股份：427.31K，占总股份比例：2.28%。
Tang Capital Management, LLC持有股份：360.86K，占总股份比例：1.93%。
Samsara BioCapital, LLC持有股份：11.45M，占总股份比例：61.21%。
ElevateBio LLC持有股份：724.99K，占总股份比例：3.88%。
Ferrara (Napoleone)持有股份：504.00K，占总股份比例：2.69%。
F2 MG Ltd持有股份：427.31K，占总股份比例：2.28%。
Tang Capital Management, LLC持有股份：360.86K，占总股份比例：1.93%。
Kalaris Therapeutics Inc的前三大股东类型是什么？
Kalaris Therapeutics Inc 的前三大股东类型分别是：
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
有多少机构持有Kalaris Therapeutics Inc(KLRS)的股份？
截至2025Q3，共有193家机构持有Kalaris Therapeutics Inc的股份，合计持有的股份价值约为13.23M，占公司总股份的70.72%。与2025Q2相比，机构持股有所增加，增幅为-17.94%。
哪个业务部门对Kalaris Therapeutics Inc的收入贡献最大？
在FY2021，--业务部门对Kalaris Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
